Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study

Harvard University, Cambridge, Massachusetts, United States
Contraception (Impact Factor: 2.93). 09/2006; 74(2):133-40. DOI: 10.1016/j.contraception.2006.02.008
Source: PubMed

ABSTRACT Topical microbicides against the human immunodeficiency virus (HIV) 1 that are nonirritating to the female genital epithelium are urgently needed to slow the heterosexual spread of HIV infection. Products that are also effective contraceptives provide additional benefits. Cellulose sulfate (CS) is a noncytotoxic antifertility agent that exhibits in vitro antimicrobial activity against sexually transmitted pathogens, including HIV.
We performed a multicenter, Phase I, placebo-controlled, randomized study to evaluate the genital toxicity of CS. Two cohorts of healthy women used 3.5 ml of 6% CS gel or 3.5 ml of K-Y Jelly, vaginally, bid, for 14 days. The first cohort was sexually abstinent, and the second cohort was sexually active.
CS was associated with only a slightly higher odds ratio (OR) of symptoms of minor urogenital irritation compared to the inactive lubricant K-Y Jelly (OR=2.02, 95% confidence interval=0.90-4.53). In addition, there were minor shifts in some genital flora, but there was no evidence of greater inflammation as evidenced by few colposcopic findings, decreased influx of polymorphonuclear cells and minimal changes in proinflammatory cytokines. Moreover, both products appeared acceptable to most women. Product leakage was identified as more of a problem in sexually abstinent women, but less so in women using the product for sexual intercourse, as would be the case in actual practice.
CS was safe for twice-daily use for 14 days. CS is appropriate for future studies in effectiveness trials.

Download full-text


Available from: Susan A Ballagh, Jun 27, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of topical microbicides for intravaginal use to prevent HIV infection requires that the drugs and formulated products be nontoxic to the endogenous vaginal Lactobacillus. In 30min exposure tests we found dapivirine, tenofovir and UC781 (reverse transcriptase inhibitor anti-HIV drugs) as pure drugs or formulated as film or gel products were not deleterious to Lactobacillus species; however, PSC-RANTES (a synthetic CCR5 antagonist) killed 2 strains of Lactobacillus jensenii. To demonstrate the toxicity of formulated products a new assay was developed for use with viscous and non-viscous samples that we have termed the Lactobacillus toxicity test. We found that the vortex mixing of vaginal Lactobacillus species can lead to reductions in bacterial viability. Lactobacillus can survive briefly, about 2s, but viability declines with increased vortex mixing. The addition of heat inactivated serum or bovine serum albumin, but not glycerol, prevented the decrease in bacterial viability. Bacillus atrophaeus spores also demonstrated loss of viability upon extended mixing. We observed that many of the excipients used in film formulation and the films themselves also afford protection from the killing during vortex mixing. This method is of relevance for toxicity for cidal activities of viscous products.
    Journal of microbiological methods 02/2012; 88(2):292-6. DOI:10.1016/j.mimet.2011.12.013 · 2.10 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Colposcopy is commonly used for genital tract assessment in safety studies on female-controlled vaginal products. However, findings that are considered "lesions" are present even without product use. We sought to categorize the type and frequency of lesions found on baseline colposcopy evaluation in healthy women to describe natural lower genital tract changes due to environmental factors. We reviewed demographic information and baseline colposcopic examination findings from subjects in 13 studies of vaginal products. All studies included an aim of identifying colposcopic changes as a means of monitoring safety of a vaginal product or device. Colposcopic evaluations were performed according to the WHO/CONRAD Manual for the Standardization of Colposcopy for the Evaluation of Vaginal Products. A total of 317 lesions were found on 569 baseline colposcopy evaluations, with 192 women (34%) having at least one lesion. The most commonly identified lesions were petechiae and erythema, accounting for 45% and 37% of lesions, respectively. Seventy-three percent of lesions were located on the cervix, whereas 15% of lesions were located on the vaginal wall or fornix. Lower genital tract colposcopic findings are common in healthy women. Such findings likely represent normal physiologic changes. Future research needs to address whether routine colposcopic examination is necessary in the evaluation of new vaginal products.
    Contraception 09/2008; 78(2):162-6. DOI:10.1016/j.contraception.2008.04.002 · 2.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Human immunodeficiency virus type 1 (HIV-1) entry into cells is mediated by the functional envelope spike, which consists of trimers of gp120 bound to gp41. Most variants of HIV-1 enter cells through attachment of the envelope spike to the main cellular receptor CD4, allowing interaction with a co-receptor and eventually fusion of viral and cellular membranes. Neutralising antibodies inhibit HIV-1 entry by targeting epitopes on the functional spike. HIV-1 has, however, evolved several ways to evade recognition by antibodies, including variable regions, carbohydrates, and conformational masking. As a result, the neutralising antibody response in HIV-1 infection and post-immunisation is generally narrow, and only a handful of broadly neutralising monoclonal antibodies have been reported. In this thesis, the isolation and characterisation of novel, broadly neutralising antibody fragments derived from llamas is described. Llamas produce antibodies devoid of light chains, which have their antigen-binding properties confined to a single fragment, the VHH, and a preference for cleftrecognition. VHH were isolated from llamas immunised with recombinant gp120 using phage display-based methods. In order increase the chances of isolating neutralising VHH, a functional selection strategy was employed, involving a competitive elution with soluble CD4. Three VHH able to neutralise HIV-1 primary isolates of subtype B and C were characterised. These VHH bound to gp120 with high affinities and competed with soluble CD4 and antibodies to the CD4-binding site for this binding, indicating that their mechanism of neutralisation involves interacting with the functional envelope spike prior to binding to CD4. These results indicate that llama VHH can be potent HIV-1 entry inhibitors. Since VHH are stable and can be produced at a relatively low cost, they may be considered for HIV-1 microbicide development. Anti-gp120 VHH might also prove useful in defining neutralising and non-neutralising epitopes on HIV-1 envelope proteins, with implications for HIV-1 vaccine design.